Aclaris Therapeutics, Inc.
ACRS
$1.75
-$0.06-3.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.79M | 17.78M | 18.72M | 27.08M | 32.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.79M | 17.78M | 18.72M | 27.08M | 32.02M |
| Cost of Revenue | 53.09M | 50.46M | 49.04M | 61.57M | 85.28M |
| Gross Profit | -36.30M | -32.68M | -30.32M | -34.49M | -53.26M |
| SG&A Expenses | 22.13M | 21.50M | 22.20M | 24.56M | 26.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.22M | 71.96M | 71.25M | 86.14M | 111.28M |
| Operating Income | -58.43M | -54.18M | -52.53M | -59.06M | -79.26M |
| Income Before Tax | -134.65M | -130.21M | -132.07M | -37.37M | -59.05M |
| Income Tax Expenses | -- | -- | -- | -367.00K | -367.00K |
| Earnings from Continuing Operations | -134.65 | -130.21 | -132.07 | -37.00 | -58.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -134.65M | -130.21M | -132.07M | -37.00M | -58.68M |
| EBIT | -58.43M | -54.18M | -52.53M | -59.06M | -79.26M |
| EBITDA | -58.26M | -53.99M | -52.22M | -58.66M | -78.83M |
| EPS Basic | -1.37 | -1.40 | -1.51 | -0.52 | -0.83 |
| Normalized Basic EPS | -0.28 | -0.30 | -0.35 | -0.44 | -0.62 |
| EPS Diluted | -1.37 | -1.40 | -1.51 | -0.52 | -0.83 |
| Normalized Diluted EPS | -0.28 | -0.30 | -0.35 | -0.44 | -0.62 |
| Average Basic Shares Outstanding | 411.66M | 360.37M | 309.05M | 284.61M | 284.04M |
| Average Diluted Shares Outstanding | 411.66M | 360.37M | 309.05M | 284.61M | 284.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |